Eton Pharmaceuticals Files 8-K on Financials
Ticker: ETON · Form: 8-K · Filed: Mar 14, 2024 · CIK: 1710340
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
Eton Pharma dropped an 8-K detailing their financials - check it out.
AI Summary
Eton Pharmaceuticals, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits related to the company's performance.
Why It Matters
This filing provides investors with updated financial information and operational results for Eton Pharmaceuticals, Inc.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- Eton Pharmaceuticals, Inc. (company) — Registrant
- March 14, 2024 (date) — Date of Report
- 001-38738 (company) — SEC File Number
- 37-1858472 (company) — I.R.S. Employer Identification Number
- Deer Park, Illinois (location) — Principal executive offices
FAQ
What specific financial results are being reported in this 8-K?
The filing indicates it pertains to 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits', but the specific details of these results are not provided in the provided text.
When was this 8-K filing submitted?
The filing was submitted on March 14, 2024.
What is Eton Pharmaceuticals, Inc.'s principal executive office address?
The principal executive offices are located at 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010-7208.
What is Eton Pharmaceuticals, Inc.'s IRS Employer Identification Number?
The IRS Employer Identification Number for Eton Pharmaceuticals, Inc. is 37-1858472.
What is the SEC file number for Eton Pharmaceuticals, Inc.?
The SEC file number for Eton Pharmaceuticals, Inc. is 001-38738.
Filing Stats: 501 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2024-03-14 16:16:16
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share ETON NASDAQ Global Market
Filing Documents
- eton20231213_8k.htm (8-K) — 26KB
- ex_606409.htm (EX-99.1) — 167KB
- 0001437749-24-007850.txt ( ) — 334KB
- eton-20240314.xsd (EX-101.SCH) — 3KB
- eton-20240314_def.xml (EX-101.DEF) — 11KB
- eton-20240314_lab.xml (EX-101.LAB) — 15KB
- eton-20240314_pre.xml (EX-101.PRE) — 11KB
- eton20231213_8k_htm.xml (XML) — 3KB
02 Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition. On March 14, 2024, Eton Pharmaceuticals, Inc. issued a press release announcing its financial results for the fourth quarter and year ended December 31, 2023. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02 and the attached Exhibit 99.1 are being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. The information in this Item 2.02 and the attached exhibit shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit 99.1 Press Release issued by Eton Pharmaceuticals, Inc. on March 14, 2024 relating to financial results 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: March 14, 2024 By: /s/ James R. Gruber James R. Gruber Chief Financial Officer and Secretary (Principal Financial Officer) 3